AR/BET protein degrader-1

Catalog No. :
ACAFZC124
CAS No. :
2571123-81-2
Molecular Formula :
C43H44N6O5
Molecular Weight :
724.86

IUPAC Name:1-(4-((5-(3,5-dimethylisoxazol-4-yl)-2-methylphenyl)(((1r,4r)-4-(((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)amino)methyl)cyclohexyl)methyl)amino)phenyl)cyclopropane-1-carbonitrile

AR/BET protein degrader-1 structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
No pack options available.

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product NameAR/BET protein degrader-1
IUPAC Name1-(4-((5-(3,5-dimethylisoxazol-4-yl)-2-methylphenyl)(((1r,4r)-4-(((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)amino)methyl)cyclohexyl)methyl)amino)phenyl)cyclopropane-1-carbonitrile
Molecular FormulaC43H44N6O5
Molecular Weight724.86
SMILESCC1=CC=C(C2=C(C)ON=C2C)C=C1N(C[C@H]1CC[C@H](CNC2=CC3=C(C=C2)C(=O)N(C2CCC(=O)NC2=O)C3=O)CC1)C1=CC=C(C2(C#N)CC2)C=C1
InChI KeyFBORFKHYZSLIDY-ARBFJVLTSA-N
SynonymAR/BET protein degrader-1;Cyclopropanecarbonitrile, 1-[4-[[5-(3,5-dimethyl-4-isoxazolyl)-2-methylphenyl][[trans-4-[[[2-(2,6-dioxo-3-piperidinyl)-2,3-dihydro-1,3-dioxo-1H-isoindol-5-yl]amino]methyl]cyclohexyl]methyl]amino]phenyl]-
CAS No.2571123-81-2

Synthetic Route by SureRoute

1. ACAFZC124 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. ACNYZE284 route compound structure diagram
    ACNYZE28426166-92-7 In Stock
  4. Then
  5. ACAFZC124 route product structure diagram
    ACAFZC1242571123-81-2
Inquiry

2. ACAFZC124 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. ACHUST306 route compound structure diagram
    ACHUST306191732-76-0 In Stock
  4. Then
  5. ACAFZC124 route product structure diagram
    ACAFZC1242571123-81-2
Inquiry

Comments (0)